Recruiting JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658 Conditions Cutaneous T Cell Lymphoma, Cutaneous T Cell Lymphoma (CTCL), Hematologic Diseases, +22 more Locations Institute of Hematology & Blood Diseases Hospital, China — Tianjin, Tianjin Municipality, China Institute of Hematology & Blood Diseases Hospital — Tianjin, China View Trial Details
